EuropaWire20d
AstraZeneca Presents New Data at IDWeek 2024, Showcasing Progress in Respiratory Disease Prevention and Vaccine Innovation
(IN BRIEF) AstraZeneca presented significant advancements in the prevention of infectious diseases at IDWeek 2024, showcasing its dedication to addressing respiratory infections caused by RSV, hMPV, ...
2minutemedicine.com22d
AstraZeneca’s FluMist first and only self-administered flu vaccine
FluMist is an efficacious and safely tolerated intranasal influenza vaccine. FluMist has gained approval from the FDA for self-administration by patients aged 18-49. FluMist is the first influenza ...
Morningstar26d
AstraZeneca Holds a Strong Portfolio and Pipeline That Support Solid Long-Term Growth
AstraZeneca has built its leading presence in the pharma and biotech industry on patent-protected drugs and a developing pipeline that add up to a wide moat. The strong replenishment of new drugs ...
Outsourcing-pharma26d
AstraZeneca licenses CSPC’s cardiovascular drug in $2 billion deal
The big pharma company AstraZeneca has forged a licensing pact worth $2 billion with the Chinese firm CSPC Pharmaceutical Group for access to an experimental small molecule treatment for dyslipidemia.
Chemistry World27d
AstraZeneca synthetic chemistry prize winner celebrates ‘culmination of a high-quality academia-industry collaboration’
The 2024 AstraZeneca prize in synthetic chemistry has been awarded to Ruth Webster, University of Cambridge, for her productive early career and innovative research, particularly in iron catalysis, ...
FinanceAsia28d
AstraZeneca signs license agreement with China’s CSPC worth up to $2bn
UK pharmaceutical giant AstraZeneca has entered into an exclusive license agreement with China's CSPC Pharmaceutical Group (CSPC) to advance the development of an early stage, novel small molecule ...
PharmiWeb29d
AstraZeneca strengthens its cardiovascular pipeline with agreement for a pre-clinical novel lipid-lowering therapy
AstraZeneca has entered into an exclusive license agreement with CSPC Pharmaceutical Group Ltd (CSPC) to advance the development of an early stage, novel small molecule Lipoprotein (a) (Lp(a)) ...
clinicaltrialsarena29d
AstraZeneca’s Phase III trial of treatment for asthma meets its primary endpoint
AstraZeneca’s Airsupra is currently approved in the US for as-needed treatment or prevention of bronchoconstriction. Credit: Jennie Book/Shutterstock. UK-based pharmaceutical company AstraZeneca has ...
Business Times29d
AstraZeneca signs US$1.92 billion licensing deal with HK-listed CSPC
AstraZeneca said on Monday (Oct 7) it would pay up to US$1.92 billion to CSPC Pharmaceutical Group in an exclusive licence agreement to boost the Anglo-Swedish drugmaker’s cardiovascular pipeline.
FiercePharma29d
AstraZeneca heads to regulators after Airsupra asthma trial stops early thanks to 'overwhelming efficacy'
After winning a first-in-class nod for its two-drug inhaler Airsupra last January, AstraZeneca is adding to the thesis that the drug can cut the risk of asthma exacerbations regardless of disease ...
Reuters29d
AstraZeneca signs $1.92 bln licencing deal with HK-listed CSPC
Oct 7 (Reuters) - AstraZeneca (AZN.L), opens new tab said on Monday it would pay up to $1.92 billion to CSPC Pharmaceutical Group Ltd (1093.HK), opens new tab in an exclusive licence agreement to ...